2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 677

Antibodies to Oxidized Low Density Lipoprotein or Anti-Lipoprotein Lipase May Lead to More Atherosclerotic Plaque in a Sub-Set of SLE Patients
Abstract Number: 1748

Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies
Abstract Number: 948

Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of 12,555 Patients with Antinuclear Antibody Testing
Abstract Number: 2190

Antimalarials for Sjogren’s Syndrome Treatment in Adults, Meta-Analysis
Abstract Number: 1421

Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease
Abstract Number: 1730

Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus
Abstract Number: 2366

Aortic and Coronary Calcifications in Takayasu Arteritis
Abstract Number: 2255

Apolipoprotein B Containing Lipoprotein Subclasses and Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 729

Apolipoprotein L1 Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease
Abstract Number: 2237

Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic
Abstract Number: 2226

Application of Classification Criteria for Psoriatic Arthritis to Patients of the Rotterdam Early Arthritis Cohort
Abstract Number: 1436

Application of European League Against Rheumatism Recommendations for the Management of Systemic Lupus Erythematosus Patients with Neuropsychiatric Involvement May Limit Unnecessary Diagnostic Testing and Curve Intensification of Immunosuppressive Therapy of Unclear Benefit
Abstract Number: L13

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial
Abstract Number: 1996

Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Abstract Number: 2431

Are Occupational Therapy Interventions Included in the Most Commonly Used European Clinical-Practice Guidelines for the Management of Osteoarthritis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].